AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$ARDX

Bishop John E sold $76K of ARDX

Bishop John E (See Remarks) sold 19,750 shares of ARDELYX, INC. (ARDX) at $3.86 across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Bishop John E
Published Aug 25, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARDX
Bearish
medium confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXBearishLow
01

Why it matters

The disclosed sale is modest in dollar terms but involves an officer, which may be watched by traders for sentiment cues.

02

Market read

Routine insider sale with limited trading impact.

03

What to watch

Potential upcoming clinical data releases that may offset any negative sentiment from the sale.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$ARDXBearishMedium confidence
Context

Officer Bishop John E sold 19,750 shares for $76,173 in a Form 4 filing on 2026-08-25.

Expected impact

Potential modest downward pressure on ARDX price.

Evidence & confidence

The sale size is modest ($76K) but involves an officer, which can influence short-term perception.

Market effects

Sector

Minimal impact on the biotech sector; typical insider sales are routine.

Regional

No regional effect; limited to ARDX shareholders.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Officer
    Bishop John E

    Insider who sold shares.

  • Company
    ARDELYX, INC.

    Biotech firm listed under ticker ARDX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARDX insider trading history →

Related articles

AUG 14
$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

fool.com6 min
AUG 7
$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

investing.com4 min
AUG 6
$ARDXMed

ARDELYX, INC. (ARDX): Results of Operations and Financial Condition

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow

SEC EDGAR 8-K5 min